The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Mar. 20, 2018

Filed:

Aug. 05, 2016
Applicant:

University Hospitals Cleveland Medical Center, Cleveland, OH (US);

Inventors:

John R. Haaga, Chagrin Falls, OH (US);

Rebecca Haaga, Chagrin Falls, OH (US);

Assignee:
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/196 (2006.01); A61K 31/44 (2006.01); A61K 39/395 (2006.01); A61K 47/30 (2006.01); C07K 16/22 (2006.01); A61K 45/06 (2006.01); A61K 31/195 (2006.01); A61K 9/00 (2006.01); A61K 47/34 (2017.01); A61B 5/055 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
A61K 31/196 (2013.01); A61K 9/0019 (2013.01); A61K 31/195 (2013.01); A61K 31/44 (2013.01); A61K 39/39558 (2013.01); A61K 45/06 (2013.01); A61K 47/34 (2013.01); C07K 16/22 (2013.01); A61B 5/055 (2013.01); A61K 2039/505 (2013.01); C07K 2317/24 (2013.01); C07K 2317/76 (2013.01);
Abstract

The present invention relates to a pharmaceutical cocktail and methods of treatment involving said cocktail, in particular, a combination of effective amounts of a carbonic anhydrase inhibitor, in combination with effective amounts of an angiogenesis inhibitor, including a vascular endothelial growth factor (VEGF) inhibitor such as bevacizumab for the treatment of cancer. In other embodiments, it relates to compositions and methods of treating cancer involving effective amounts of a carbonic anhydrase inhibitor. Pharmaceutical compositions and methods of treating cancer (eliminating the tumor, shrinking the tumor, prolonging the life of the patient, increasing quality of life by decreasing the grade of adverse events seen with other cancer treatments, and/or preventing/reducing the likelihood of the tumor's metastases) are additional aspects of the present invention. In addition, the present invention may be used to favorably impact the therapeutic result of patients who have not responded to alternative, traditional anti-cancer therapy.


Find Patent Forward Citations

Loading…